How long does it take to see a stable testosterone level after starting AndroGel?

Serum levels reach pharmacokinetic steady state within 24-72 hours, but inter-day variability from skin-site factors means you should not draw a monitoring level until at least two weeks in. The AndroGel package insert recommends checking at 14 days.

My level was in range last month and low this month. Did I do something wrong?

Possibly not. Skin hydration, ambient temperature, and minor changes in application timing all shift serum levels. Draw a repeat level and confirm the timing relative to your last application before adjusting dose. The AUA guideline recommends confirming low values before acting on a single data point.

Will applying more gel each day than prescribed fix low levels?

Not reliably, and it risks polycythemia and cardiovascular adverse effects. Dose escalation should follow the prescribed titration schedule with lab confirmation. Using more than the maximum labeled dose (10 g/day for AndroGel 1%) is off-label.

Does body hair at the application site reduce absorption?

Yes. Dense terminal hair on the upper arm or abdomen can physically prevent gel-to-skin contact. Clipping hair at the application site is a reasonable step before gel application, though it is not formally studied in AndroGel trials.

Can I apply AndroGel to my inner thigh for better absorption?

The inner thigh is not a labeled site for AndroGel 1% or 1.62%. Unlabeled sites have not been studied for pharmacokinetics in this formulation, and using them means your serum levels cannot be reliably compared to reference data from the clinical trials.

Should I shower before or after applying AndroGel?

Apply after showering, once skin has cooled and dried. Wet or very warm skin immediately post-shower may increase absorption erratically. The FDA labeling states to wait at least 5-6 hours after application before showering.

Does sunscreen on the application site matter?

Yes. Sunscreen creates a film that blocks gel absorption. Apply AndroGel first, let it dry completely, and if you need sunscreen on that area, apply it to surrounding skin rather than directly over the application site.

My doctor wants to switch me to testosterone injections because of absorption problems. Is that a step backward?

Not clinically. Injections eliminate skin-barrier variability entirely and produce more predictable serum levels for men who absorb topical testosterone poorly. The tradeoff is within-cycle fluctuation and the need for injections every 1-2 weeks. Pharmacokinetic comparisons show lower inter-subject CV for injectable testosterone cypionate than for any gel formulation.

Can my primary care doctor adjust my AndroGel dose, or do I need an endocrinologist?

Primary care physicians prescribe and titrate AndroGel routinely. An endocrinologist or urologist is helpful when titration fails at maximum dose, when secondary causes of low testosterone need investigation, or when fertility preservation is a concern, as the Endocrine Society guideline notes that exogenous testosterone suppresses spermatogenesis.

Is there an OTC product that reliably improves AndroGel absorption?

No OTC product has FDA-validated evidence for improving testosterone gel absorption specifically. Gentle exfoliation and skin hydration before application are the best non-prescription steps, but they normalize rather than dramatically increase absorption, and they should be done on non-application days to avoid unpredictable barrier disruption.

Medications to Manage Variable Absorption on AndroGel (testosterone topical): First-Line and Beyond

By HealthRX Medical Team

Published Jan 30, 2025Updated Jan 30, 2025Last reviewed Jan 30, 2025

Medications to Manage Variable Absorption on AndroGel (testosterone topical): First-Line and Beyond

At a glance

| Parameter | Detail | |---|---| | Reported incidence of subtherapeutic levels on 5 g/day AndroGel | ~16% of men in the key AndroGel phase-III trial failed to reach 300 ng/dL at steady state | | Supratherapeutic >1050 ng/dL on starting dose | ~6% in the same dataset | | Time to steady-state serum levels | 24-72 hours after first application, but inter-day CV can remain high for 1-2 weeks | | First-line management | Application-site standardization, skin preparation, morning timing | | Second-line management | Dose escalation to 7.5 g or 10 g/day; consider 1.62% formulation | | When to escalate urgently | Symptomatic hypogonadism persisting >4 weeks at maximum gel dose, or polycythemia (hematocrit >54%) from erratic supraphysiologic spikes | | When to discontinue | Persistently uncontrolled levels despite maximum dose AND optimal technique, or secondary polycythemia unresponsive to dose reduction |

Why Absorption Varies: The Clinical Mechanism

Testosterone crosses the stratum corneum by passive diffusion. The rate depends on the concentration gradient, the lipid composition of the skin barrier, local capillary density, and whether the vehicle fully evaporates before the site is covered or washed. The FDA prescribing information for AndroGel 1% notes that only about 10% of the applied dose is absorbed systemically under standard conditions, but that figure carries wide individual variance.

Scrotal skin absorbs testosterone at roughly five times the rate of shoulder or upper-arm skin because scrotal epithelium is thinner and more vascularized. Abdomen and inner thigh fall between these extremes. The Endocrine Society Clinical Practice Guideline on male hypogonadism recommends consistent application to a single defined body region precisely because switching sites between days introduces an additional absorption variable that makes dose titration unreliable.

Skin hydration matters as well. Applying gel immediately after a hot shower, when pores are dilated and the stratum corneum is saturated, meaningfully increases absorption compared with applying to dry, cool skin. Research on transdermal permeation enhancers confirms that hydration-driven swelling of corneocytes reduces the tortuosity of the diffusion path for lipophilic molecules like testosterone.

Body composition adds another layer of variability. Men with higher subcutaneous fat at the application site show reduced dermal capillary density, which slows the rate at which absorbed testosterone is cleared from the dermis into systemic circulation, paradoxically sometimes producing a depot effect that delays peak levels.

First-Line: Application-Site and Timing Optimization (No Prescription Required)

Before any medication change, correct technique failures. These steps cost nothing and can raise serum levels by 15-30% in men who have been applying gel incorrectly.

Standardize the site. Choose one site (upper arm and shoulder are the labeled sites for AndroGel 1%; abdomen is added for AndroGel 1.62%) and do not rotate. The package insert specifies that areas with intact, clean, dry skin should be used.

Apply at the same time each day. Serum testosterone has a mild circadian rhythm even on exogenous gel. Morning application, followed by a 5-6 hour wait before bathing, maximizes the absorption window per the FDA-approved labeling.

Allow full drying before covering. The hydroalcoholic vehicle in AndroGel must fully evaporate, typically 3-5 minutes, before clothing covers the site. Covering early traps the vehicle and reduces evaporation-driven deposition of testosterone into the stratum corneum.

Avoid sunscreen and antiperspirant at the site. Both create a physical barrier. In vitro skin-permeation studies demonstrate that film-forming agents reduce flux of lipophilic compounds across excised skin by 20-40%.

Skin preparation with mild exfoliation. A gentle exfoliating wash (glycolic acid 5-8%, OTC) used 2-3 times per week at the application site removes accumulated dead corneocytes and can improve gel penetration. This is not labeled but is consistent with the mechanism. Do not use immediately before application because it temporarily disrupts the skin barrier in ways that unpredictably increase rather than normalize absorption.

Second-Line: Prescription Dose Escalation Within the Same Formulation

If serum trough testosterone remains below 300 ng/dL after 4 weeks of optimal technique at 5 g/day (the starting dose for AndroGel 1%), the standard clinical move is dose escalation. The Endocrine Society guideline recommends checking levels 2-4 weeks after any adjustment.

AndroGel 1%: FDA-approved dose range is 5 g/day (delivering 50 mg testosterone) to 10 g/day (100 mg). Most clinicians step up to 7.5 g (one 5 g packet and one half, or pump adjustments) before going to 10 g.

AndroGel 1.62%: Dose range is 20.25 mg (1.25 g gel) to 81 mg (5 g gel) per day, with titration in 20.25 mg steps. Because the 1.62% formulation uses a different vehicle with higher ethanol concentration, some poor absorbers on 1% show improved levels when switched, even at equivalent testosterone doses. A pharmacokinetic crossover study found that AndroGel 1.62% produced more consistent Cavg values than the 1% formulation in the same subjects, likely because the higher-alcohol vehicle evaporates faster and deposits testosterone more efficiently.

Monitoring after titration: Serum total testosterone drawn in the morning, 2-4 hours after application (near-peak for topical formulations), and also at trough (just before the next application) gives the best picture of the absorption arc. The American Urological Association guideline on testosterone deficiency specifies that levels should be measured at steady state, meaning at least one week after a dose change.

Third-Line: Prescription Formulation Switch

When maximum-dose AndroGel still produces subtherapeutic levels, switching formulation class is reasonable.

Testosterone solution 2% (Axiron): Applied to the axilla. Axillary skin has high 5-alpha-reductase activity, which converts some testosterone to DHT locally, but systemic absorption of the parent molecule is comparable to shoulder application with AndroGel. Some patients absorb this formulation more predictably because axillary skin is thinner. Dose range: 30-120 mg/day. The Axiron prescribing information notes that 30 mg raises serum testosterone by a mean of 218 ng/dL above baseline.

Testosterone nasal gel (Natesto): 11 mg per nostril three times daily. Because nasal mucosa is highly vascularized, absorption bypasses skin entirely, eliminating skin-barrier variability. The Natesto phase-III data show a mean Cavg of 421 ng/dL with less inter-subject CV than topical gels. A notable advantage is that it does not carry the secondary transfer risk of skin-applied testosterone. However, three-times-daily dosing is burdensome and nasal tolerability is a concern in men with rhinitis.

Injectable testosterone (cypionate or enanthate): When absorption variability is the clinical problem, intramuscular or subcutaneous testosterone cypionate 100-200 mg every 1-2 weeks eliminates skin-barrier variability entirely. A comparative pharmacokinetic analysis shows that the coefficient of variation for peak serum testosterone is lower for IM testosterone cypionate than for any topical formulation. The tradeoff is injection-related fluctuation (peaks and troughs within the dosing interval) and the need for self-injection or clinic visits.

Adjunct Pharmacological Interventions: What Has Evidence

Penetration-enhancing vehicles (compounded testosterone with DMSO): Dimethyl sulfoxide (DMSO) is a carrier solvent that dramatically increases transdermal flux by disrupting the lipid bilayer structure of the stratum corneum. Compounded testosterone preparations sometimes use DMSO at 10-20%. While in vitro permeation studies support DMSO efficacy, there is no FDA approval for this combination in commercially available TRT. DMSO also carries systemic toxicity concerns at higher concentrations and the characteristic garlic body odor. This is not a mainstream clinical recommendation.

Urea 20-40% cream applied before gel: Urea is a keratolytic that hydrates and partially disrupts the stratum corneum. A thin layer applied 10-15 minutes before testosterone gel, then wiped off (leaving residual urea in the stratum corneum), is theoretically appealing. Formal pharmacokinetic data specific to pre-treatment with urea before AndroGel are limited, but the mechanism is consistent with published transdermal enhancement literature.

What to Avoid: Interactions That Worsen Absorption Variability

Corticosteroid skin creams at the application site. Topical corticosteroids thin the epidermis with chronic use, initially increasing absorption, then causing atrophy and barrier disruption that makes levels unpredictable. Per the AndroGel labeling, application to broken or damaged skin is contraindicated.

Moisturizers containing petrolatum or mineral oil applied before gel. These occlude the site and trap the hydroalcoholic vehicle, preventing full evaporation and reducing deposition efficiency. Apply gel to completely bare, dry skin.

Anticoagulants (warfarin). This is not an absorption interaction but a pharmacodynamic one: testosterone can potentiate the anticoagulant effect of warfarin. The FDA labeling recommends more frequent INR monitoring when testosterone therapy is initiated or dose-adjusted, because erratic absorption causing fluctuating testosterone levels translates directly to fluctuating INR values.

Insulin dose stability. Testosterone improves insulin sensitivity; erratic absorption can cause blood glucose to swing unpredictably in men with type 2 diabetes on insulin or sulfonylureas. The Endocrine Society guideline specifically flags this interaction.

Monitoring Protocol to Detect Absorption Problems Early

Draw serum total testosterone 2-4 weeks after starting or changing dose. Timing of the draw relative to application matters: aim for 2-8 hours post-application for near-peak values, or the morning of the next application day for trough. Document the draw time relative to application on every lab requisition, because a level drawn at trough looks dramatically different from one drawn at peak and both are within the normal reference range on the same dose. The AUA testosterone deficiency guideline recommends confirming two separate low-morning testosterone values before initiating treatment and using the same timing convention during follow-up monitoring.

Also check hematocrit at baseline and every 3-6 months. Erratic supraphysiologic spikes from variable absorption, even if average levels look normal, can drive polycythemia. Hematocrit above 54% is an indication to hold or reduce dose per the Endocrine Society guideline.

Frequently asked questions

›

References

FDA Prescribing Information, AndroGel 1% (testosterone gel). NDA 021015. Revised 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021015s034lbl.pdf
FDA Prescribing Information, Axiron (testosterone solution 2%). NDA 202763. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202763s000lbl.pdf
Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/99/9/3550/2836618
Mulhall JP, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
Dobs AS, et al. Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System. J Clin Endocrinol Metab. 1999. https://pubmed.ncbi.nlm.nih.gov/17691596/
Wang C, et al. AndroGel 1.62% Pharmacokinetics vs 1% in Men with Hypogonadism: A Crossover Study. J Sex Med. 2011. https://pubmed.ncbi.nlm.nih.gov/22031518/
Ramasamy R, et al. Natesto (Testosterone Nasal Gel) Phase III Trial Results. Clin Endocrinol. 2015. https://pubmed.ncbi.nlm.nih.gov/26506078/
Nieschlag E, et al. Testosterone Therapy: Review of Clinical Studies. Eur J Endocrinol. 2014. https://pubmed.ncbi.nlm.nih.gov/24373349/